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Huntington’s disease (HD) is an inherited disease that causes progressive nerve cell degeneration. It is triggered by
a mutation in the HTT gene that strongly influences functional abilities and usually results in movement, cognitive
and psychiatric disorders. HD is incurable, although treatments are available to help manage symptoms and to
delay the physical, mental and behavioral declines associated with the condition. Stem cells are the essential
building blocks of life, and play a crucial role in the genesis and development of all higher organisms. Ablative
surgical procedures and fetal tissue cell transplantation, which are still experimental, demonstrate low rates of
recovery in HD patients. Due to neuronal cell death caused by accumulation of the mutated huntingtin (mHTT)
protein, it is unlikely that such brain damage can be treated solely by drug-based therapies. Stem cell-based
therapies are important in order to reconstruct damaged brain areas in HD patients. These therapies have a dual
role: stem cell paracrine action, stimulating local cell survival, and brain tissue regeneration through the production
of new neurons from the intrinsic and likely from donor stem cells. This review summarizes current knowledge on
neural stem/progenitor cell and mesenchymal stem cell transplantation, which has been carried out in several
animal models of HD, discussing cell distribution, survival and differentiation after transplantation, as well as
functional recovery and anatomic improvements associated with these approaches. We also discuss the usefulness
of this information for future preclinical and clinical studies in HD.Introduction
Huntington’s disease (HD) is believed to be due to a sig-
nificant loss of medium spiny neurons in the brain. Main
treatment efforts have, therefore, been focused on obtain-
ing new medium spiny neurons to replace the damaged
ones. One single transplantation of human fetal striatal
tissue into brains of a small number of HD patients pro-
vided short-term improvement in both movement and
psychological symptoms [1]. Tissue taken from aborted fe-
tuses, however, offers only a very limited quantity of cells,
which cannot be purified or improved. Therefore, alterna-
tive valuable sources, such as in vitro cultured, expanded
and purified neural stem cells (NSCs)/precursor cells and
mesenchymal stem cells (MSCs) are of great interest. In* Correspondence: irina.kerkis@butantan.gov.br;
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studies and in drug screening for HD [2]. It is hard to
evaluate the effect of cell therapy in vitro, however, since it
requires cell interaction of graft with host cells and tissues.
The present review will provide a short description of HD
degenerative nervous system disorder symptoms, causes,
and current treatments, as well as recent achievements in
animal studies employing NSCs/progenitor cells or MSCs
in chemical and transgenic animal HD models in order to
critically evaluate the use of the transplantation of these
cells in HD treatment.Huntington’s disease
HD is an inherited, autosomal-dominant, neurodegenera-
tive disorder that results from the expansion (36 or more
repeats) of a sequence of three DNA bases, cytosine-
adenine-guanine (CAG), within exon 1 of the huntingtin
(HTT) gene [3–5]. CAG repeat length in the mutant allele
accounts for approximately 70 % of the variability in ageis distributed under the terms of the Creative Commons Attribution 4.0
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ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Kerkis et al. Stem Cell Research & Therapy  (2015) 6:232 Page 2 of 15of onset of HD, while the number of CAG repeats in the
normal allele does not modify the age of onset [6, 7]. Trip-
let repeat length also influences disease progression, even
after controlling for age of onset [8]. HD affects all races
[9] and shows a stable prevalence in most populations of
white people, which is of about 5 to 7 affected individuals
per 100,000 [10]. The mean age of onset of HD is approxi-
mately 40 years; however, the disease may occur from in-
fancy to the ninth decade of life [11]. Median survival
time varies between 15 and 20 years from onset [12].
Clinical features of HD include progressive motor dys-
function, cognitive decline and psychiatric disturbance,
probably caused by both neuronal dysfunction and neur-
onal cell death [12]. Despite its widespread distribution,
mutant HTT (mHTT) protein causes selective neurode-
generation and neuronal loss, which occur preferentially
in the striatum and in deeper layers of the cortex at early
stages of HD [13, 14]. In advanced stages of the disease,
many other brain regions can be affected as well, such as
the globus pallidus, thalamus, hypothalamus, subtha-
lamic nucleus, substantia nigra and cerebellum [15–18].
Because of neurodegeneration, HD patients present typ-
ical involuntary movements called chorea (dance-like
movements), manifested by spontaneous and transient
muscle contractions [19, 20].
Huntington’s disease and neuronal cell loss
At a molecular level, HD is characterized by progressive
loss of GABAergic medium spiny neurons, which consti-
tute 95 % of all striatal neurons. As the disease progresses,
neurodegeneration becomes most prominent in the neos-
triatum, commonly referred to as the striatum, which also
includes the caudate nucleus and putamen. Striatal atro-
phy occurs in 95 % of HD brains, with a mean volumetric
decrease of brain matter of 58 % [14, 21].
mHTT protein is thought to cause cellular dysfunc-
tion, neurodegeneration and associated clinical features
primarily through a toxic gain of function [13]. Al-
though the physiological role of normal HTT remains
unidentified, many proteins are known to interact with
HTT, such as brain-derived neurotrophic factor (BDNF),
and this binding may be associated with HTT function
[22]. HTT is normally expressed at highest levels in the
brain, particularly in the cerebral cortex (layers II and V)
and the striatum [23, 24]. HTT is also expressed in per-
ipheral tissues, contradicting the restricted and regional
pathology of HD [25]. HTT is mostly a cytoplasmic
protein, though it is also found at low levels in the nu-
cleus in both neuronal and non-neuronal cell types in
HD [26–28]. Regarding mHTT, the pathogenic process
associated with polyGln expansion may involve an
interaction with other proteins or multimerization to
build large insoluble aggregates in the striatum and the
cortex of HD patients [14, 29–34]. Aggregates alter cellfunction by sequestering normal HTT [35], transcrip-
tion factors [36], and transport proteins [37], ultimately
leading to cell death. More recently, the accumulation
of mHTT protein in the extracellular matrix in the
brain of HD patients and in vitro spreading of these
proteins from cell to cell have also been demonstrated
[38, 39].
Huntington’s disease and brain-derived neurotrophic factor
The susceptibility of striatal neurons to atrophy in HD
has been linked to nerve growth factors such as BDNF,
which is a small dimeric protein expressed in the adult
mammalian brain and has been shown to promote the
survival of all major neuronal types and differentiation
of striatal neurons [40–42]. The use of BDNF as a bio-
marker is still debated by the scientific community.
Some reports show decreased levels of BDNF in the stri-
atum and plasma of HD patients [43] while other studies
show that BDNF gene transcription (mRNA) and protein
plasma levels are variable in peripheral blood in HD
patients and are not, therefore, good biomarkers for pre-
dicting HD onset [44]. However, experimental preclinical
studies show that BDNF has an important role in neuro-
degenerative diseases [45–48]. As a neurotrophic factor,
BDNF is vital for the growth and survival of neurons
and glia. Thus, the promotion of endogenous BDNF
upregulation may be key to neurodegenerative disease
treatment [49]. Indeed, MSC transplantation into HD
patients can serve as an alternative strategy to increase
exogenous and endogenous BDNF expression [45–47],
as has been shown, for instance, in subpopulations of
human MSCs [50].
The immune system, inflammation and Huntington’s
disease
A large body of evidence indicates that neuroinflamma-
tion has a pivotal role in the development of several
neurodegenerative diseases [51, 52]. Yet the exact under-
lying inflammatory mechanisms and the definitive im-
pact of the innate and adaptive immune systems in HD
pathology are still not fully understood. Different reports
have previously demonstrated peripheral immune system
dysfunction in HD, including an increase in innate im-
mune system plasma proteins, such as complement fac-
tors and cytokines, several of which are associated with
disease progression [53–55]. Many of the inflammatory
cytokines and chemokines found at elevated concentra-
tions in HD patient plasma (mainly interleukin (IL)6,
tumor necrosis factor (TNF) alpha and IL8), appear to
originate from hyperactive monocytes [56, 57]. The
pro-inflammatory cytokines IL6 and TNF are signifi-
cantly increased in the striatum, plasma and cerebro-
spinal fluid in mouse models and in symptomatic as
well as presymptomatic HD patients. This anomalous
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ments aimed at slowing down HD progression [51, 52].
mHTT interaction with the key kinase of the nuclear
factor kappa B (NFKB) pathway—the inhibitor of kappa
B kinase—has been shown to be one of the causes of
increased cytokine production in primary HD immune
cells in humans, via increased activation of the NFKB
signaling cascade upon stimulation with lipopolysac-
charide. Elevated cytokine and chemokine levels found
in HD patients correlate with disease progression and
can be detected as early as 16 years before disease onset
[54, 56, 58]. Patient blood cytokine composition and
expression levels may be useful to establish the initial
moment of therapeutic intervention. Patient blood sig-
natures may also provide insights into the effects of HD
on the brain, as well as serve as biomarkers of disease
progression [59].
Animal models of Huntington’s disease
It is of major concern that preclinical studies of neurode-
generative disease have failed to predict efficacy in the
clinic. In some cases, this is a consequence of inappropri-
ate use of the model system [60]. The models most fre-
quently used in preclinical and academic studies are
chemical and transgenic HTT fragment models, and most
studies use chemical models for inducing HD, whereby
HD-like symptoms are induced by quinolinic acid (QA)
[61–67] or 3-nitropropionic acid (3-NP) [68, 69]. QA can
be found endogenously, where it binds and activates the
N-methyl-D-aspartate receptor, which is a glutamate re-
ceptor and ion channel protein found in nerve cells. At
high concentrations it is neurotoxic by over-exciting
the same receptors, eventually leading to neuronal cell
death [70]. QA is used to induce neurodegeneration in
animal models, including HD. 3-NP is also used to in-
duce neurotoxicity via oxidative stress in striatum neur-
onal mitochondria. The effect is acute and variable and
it depends on the animal, causing weight loss, lethargy,
loss of motor control and atrophy in the striatum asso-
ciated with neurodegeneration and death. Neither of
these two chemical models reproduces the molecular
events of neurodegenerative diseases and, in particular,
of HD [71].
In preclinical studies of drugs for treating HT, the
HTT fragment transgenic models are most widely used.
These include mouse models such as N1T1-82Q2, R6/2,
and R6/2-J2, all of which have a short mutated amino-
terminal fragment of human HTT. These mouse models
are all generated by the expansion in the CAG repeat of
the first exon of HTT, causing symptoms similar to
those observed in HD patients [62, 72] such as HTT ag-
gregation, jerky movements and striatal atrophy [73].
The R6/2 andR6/2-J2 models have a well-characterized
homogeneous phenotype and the advantage that it ispossible to perform survival studies in a short time
(3 months) [72]. N171-82Q mice have a longer HTT
amino-terminal fragment than R6/2 mice, with 82 poly-
glutamines, and the N171-82Q phenotype is similar to,
but less severe than, that of R6/2 and R6/2-J2 mice [74]. A
variety of transgenic animal models of HD have been
established and provide important insight into the patho-
genesis of HD, but it is important to choose appropriate
models in the specific case of evaluating the effects of
stem cell transplantation. For instance, models that de-
velop the disease quickly are adequate for short-term
treatment studies, whereas genetic models that develop
HD slower and for longer periods are best for the evalu-
ation of long-term treatments. Complete information
about HD animal models has already been published [75].
Stem cells in Huntington’s disease animal models
As mentioned above, one of the therapeutic approaches
to HD is the use of stem cell-based transplantation. Here
we discuss two main strategies of HD stem cell-based
therapies: the use of NSCs/progenitor cells (Table 1) and
the use of MSCs (Table 2). Generally, experimental pro-
tocols vary with regard to the HD animal model used,
including differences in the origin of transplanted stem
cells, the duration of in vitro stem cell expansion, the
number of stem cell passages, expression of stem cell
markers, cryopreservation, quantity of cells for trans-
plantation, route of administration, time taken between
transplantation and analysis, disease recovery, labeling
and tracking of transplanted cells, evaluation of end-
point of stem cell migration and differentiation after
transplantation, and so on. Each of these aspects has
their advantages and disadvantages, many of which are
discussed in this review.
Neural stem cells/progenitor cells
Fetal- or adult-derived NSCs/progenitor cells are consid-
ered an attractive source for cell therapy because they
are already committed to neural differentiation. Primary
cultures [62, 65] and fetus-derived immortalized cell
lines [61, 63, 68, 69], as well as progenitor stem cells
from central nervous system (CNS) brain tissues [66,
67], have been used in animal studies. NSCs/progenitor
cells, when undifferentiated, express markers such as
vimentin (present in migrating neural crest cells and in
neural stem cells of the adult CNS) [64, 69], nestin
(expressed predominantly in NSCs/progenitor neural
cells) [61, 63, 64, 69], the transcription factor SRY (sex
determining region Y)-box 2 (Sox2; known to be
expressed at high levels in the neuroepithelium of the
developing CNS) [66, 67], and other neuronal and glial
markers, such as Abcg2 (ATP-binding cassette, sub-
family G (WHITE), member 2) [69] and glial fibrillary
acidic protein (Gfap) [61]. Such adult-derived NSCs/
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3-NP 3-nitropropionic acid, BDNF brain-derived neurotrophic factor, BrdU bromodeoxyuridine, CNTF ciliary neurotrophic factor, DARPP-32 dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa, EGFP enhanced
green fluorescent protein, EPN entopeduncular, GABA gamma aminobutyric acid, GAD glutamate decarboxylase, GFAP glial fibrillary acidic protein, GP globus pallidus, HD Huntington’s disease, HN human-specific
marker to nuclear antigen, huNSC human neuronal stem cell, IV intravenous, LacZ beta galactosidase, LGE lateral ganglionic eminence, MGE medial ganglionic eminence, mNSC murine neuronal stem cell, MRI magnetic
resonance imaging, NPC neuronal progenitor cells, NSC neuronal stem cell, NTD no tumorigenesis detected, QA quinolinic acid, rNPC rat neuronal progenitor cells, rNSC rat neuronal stem cell, SCF stem cell factor, SNpr












Table 2 Mesenchymal stem cell transplantation in animal models of Huntington’s disease






























































rBM-MSCs Not specified Not
specified





QA rat 7 days
after
lesion





















































































































































































at 24 h; 4.5 % at
































WT mice 8 weeks
post-
graft
Not applied Survival rate-
significant


































































Same as above Same as above
[124]
3-NP 3-nitropropionic acid, ASC adult stem cell, AT-ASC adipose tissue-derived adult stem cell, AT-MSC adipose tissue-derived mesenchymal stem cell, BDNF brain-derived neurotrophic factor, bFGF basic fibroblast growth factor,
BM-MSC bone marrow-derived mesenchymal stem cell, CNTF ciliary neurotrophic factor, DARPP-32 dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa, EGF epithelial growth factor, FGF-2 fibroblast growth factor 2,
GABA gamma aminobutyric acid, GAD glutamate decarboxylase, GFAP glial fibrillary acidic protein, GFP green fluorescent protein, GM-CSF granulocyte-macrophage colony-stimulating factor, HGF hepatocyte growth factor,
hMSC human mesenchymal stem cell, IGF-1 insulin-like growth factor 1, KDR kinase insert domain receptor, MHC major histocompatibility complex, MSC mesenchymal stem cell, mUCB mouse umbilical cord blood, NGF nerve
growth factor, PDGF platelet-derived growth factor (alpha polypeptide), PGC-1α peroxisome proliferator-activated receptor-γ coactivator 1 α, QA quinolinic acid, rBM-MSC rat bone marrow-mesenchymal stem cell, SCF stem cell
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histocompatibility complex (MHC) class II antigens [76],
and exhibit high survival rates when transplanted into
normal adult rat brains [77, 78].
Neural stem cells/progenitor cells in vivo and the host
immune system
Whether or not NSCs/progenitor cells, similarly to MSCs,
exhibit therapeutic action—cell replacement and neuro-
protection—the immunomodulatory effects of NSCs/pro-
genitor cells still remain to be studied in depth [79].
Neuroprogenitor cells have a suppressive effect on T cells
that is accompanied by a significant decrease in proin-
flammatory cytokines such as IL2, TNFα, and interferon-γ
[80]. Moreover, NSCs/progenitor cells inhibit multiple in-
flammatory signals, as exemplified by the attenuation of
T-cell receptor-, IL2-, and IL6-mediated immune cell acti-
vation and/or proliferation [81]. However, the transplant-
ation of fetal NSCs/progenitor cells and embryonic stem
cell-derived NSCs/progenitor cells into patients and in
mice with Parkinson’s disease revealed an immune re-
sponse [82, 83], which may be explained by the presence
of microglia or astroglia in the primary cell suspension,
which strongly express MHC class II molecules [84].
Routes of neural stem cell/progenitor cell transplantation
In the majority of studies carried out with HD models,
NSCs/progenitor cells are transplanted directly into the
striatum, where they show good survival and distribution
predominantly in the damaged areas of the brain [61–63,
65–69]. However, these cells demonstrate limited migra-
tion in scar tissue [68]. In contrast, cells injected in the tail
vein are associated with a wider brain distribution [63]
and are found in the lesioned brain hemisphere, especially
near blood vessels and in the parenchyma. Additionally,
NSCs/progenitor cells are also found in peripheral organs,
such as in the renal cortex, the spleen and the bronchiole
epithelium [63] (Table 1). Intravenous (IV; systemic) ad-
ministration of NSCs/progenitor cells also shows cell re-
tention in lung capillaries directly post-injection, resulting
in inflammation and apoptosis in lung tissue [85].
Neural stem cells/progenitor cells in Huntington’s disease
animal models
NSC/progenitor cell transplantation has been carried
out in several animal studies for treatment of HD, as
summarized in Table 1. Different cell sources and prep-
aration methods have been used: single cell suspension
of primary culture of NSCs/progenitor cells [61, 62, 67]
or neurospheres formed by NSCs/progenitor cells de-
rived from brain tissue [62, 65, 66]. Several studies did
not evaluate the expression of specific NSC/progenitor
cell markers before transplantation into the animal
model [62, 65, 68] (Table 1). The number of cells andcell passages and the cell labeling for tracing vary be-
tween the studies (Table 1).
Data on the capacity of NSCs/progenitor cells to differ-
entiate into neurons in vivo are controversial; most studies
demonstrate differentiation into neurons and glial cells
[62, 63, 65–69], while a few report that transplanted cells
remain undifferentiated [61, 62]. Glutamate decarboxylase
(GAD)1 (also known as GAD67), is an important marker
of neural differentiation in HD. It catalyzes the synthesis
of gamma-aminobutyric acid (GABA), a neurotransmitter
that promotes synaptogenesis and protection from neural
injury. High GAD1 levels are, therefore, an important
marker of recovery in HD patients. Parvalbumin and
calbindin-D28k are calcium binding proteins expressed in
GABAergic interneurons. The expression of these proteins
was observed in four studies that used adult subventri-
cular zone-derived rat NSC allotransplantation [66, 67]
and immortalized fetal tissue-derived human NSC xeno-
transplantation [64, 69]. Expression of GAD1, calbindin-
D28k and/or DARPP-32 (dopamine- and cAMP-regulated
phosphoprotein, Mr 32 kDa) was observed in four studies
[66, 67], while glial fibrillary acidic protein (GFAP) expres-
sion was seen in the majority of studies [62, 63, 65–67, 69]
(Table 1). In one study [63], which used IV injection of
immortalized cell line-derived human NSCs, expression
of early markers of neuronal differentiation was found
2 months post-graft.
For successful therapeutic use of NSCs/progenitor cells
in HD, it is likely that they need to differentiate into func-
tional neuronal cells that can aid patient recovery. Differ-
ences in cell biodistribution between neurospheres, which
do or do not express ciliary neurotrophic factor (CNTF),
has been observed in HD models. Neurospheres that lack
expression of CNTF demonstrate better migration activity
in comparison with those that express this factor [65].
The migration ability of NSCs/progenitor cells in the
transgenic HD R6/2 model differed from that in a QA
chemical model [62]. Moreover, neuronal differentiation
into GABAergic and dopaminergic neurons was only
observed when using cell allotransplantation in the QA
model [66, 67] as opposed to the genetic model. Interest-
ingly, one study demonstrated that neurospheres show
better graft survival compared with cell suspensions, but
differentiate to GFAP-positive cells, usually astrocytes, in-
stead of neuronal cells [62]. This information is relevant
for future stem cell-based therapies and should be thor-
oughly verified.
An important issue regarding cell transplantation is the
possibility of induction of tumorigenesis. Only two studies
have tested the tumorigenic potential of NSCs/progenitor
cells in normal animals and did not find any type of
pathology. The absence of tumorigenic potential is an ex-
tremely important characteristic of NSCs/progenitor cells
that are to be used therapeutically. Considering that
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bryo/fetal tissues, which are immature and commonly as-
sociated with tumorigenesis, further studies are needed to
guarantee that NSC/progenitor cell transplantation is not
tumorigenic [63, 64].
Although NSC/progenitor cell transplantation has
been shown to be sufficient to induce moderate func-
tional and anatomical recovery in chemical HD models,
with increased striatal volume, reduced cellular damage
and partly induced differentiation of NSCs/progenitor
cells into glial cells and neurons [66, 67], there are still
limitations to their therapeutic use. These limitations in-
clude ethical concerns regarding the source of NSCs/
progenitor cells as well as the low quantities usually de-
rived from these sources, which hinder their use and
reliability.
Mesenchymal stem cells
MSCs are commonly found in bone marrow, umbilical
cord and fat pads [86–88]. They are responsible for tis-
sue regeneration in cases of disease or injury throughout
life. This function of MSCs is mediated by self-renewal
and plasticity (the ability to produce diverse types of dif-
ferentiated cells). MSCs can be isolated from the afore-
mentioned tissues and are easily cultured; after obtaining
a small number of cells from a patient, they can be rapidly
multiplied in vitro and cryopreserved for future clinical
applications.
MSCs are believed to be ‘cellular paramedics’ since
they secrete a variety of bioactive molecules, such as cy-
tokines, which have ‘trophic activities’ that can promote
a regenerative microenvironment, and other molecules
that contribute to reconstruction as immunomodulatory
mediators and even by carrying molecules into damaged
cells [89]. Autologous and allogeneic in vitro expanded
MSCs transplanted into the recipient organism migrate
to the injury site in response to chemotactic stimuli, and
also induce migration of intrinsic (endogenous) MSCs to
the same site from the surrounding environment. MSCs
can act by reducing chronic inflammation, inhibiting
apoptosis and scar formation and stimulating mitosis of
tissue-intrinsic progenitors, thus remodeling the damaged
tissue [90]. Due to these properties, MSCs are known as
‘medicinal signaling cells’ [89, 91, 92].
MSCs also stimulate angiogenesis, the process of new
blood vessel formation, which is closely linked to
neurogenesis, the process by which new nerve cells are
produced. Blood vessels play an important role as a
framework for neuronal progenitor cell migration to-
ward the damaged brain region. Paracrine factors se-
creted by MSCs also reduce the destructive effects of
oxidative stress. Using all these mechanisms of action,
MSCs can significantly improve lesioned microenviron-
ments that lead to restoration of the damaged tissue[92–94]. According to recent publications, MSCs can
repair neurodegeneration by secreting trophic factors
and proteins that stimulate migration, differentiation
and survival of intrinsic (endogenous) cells [89, 91, 92].
Among specific effects on nerve cells, these factors can
promote axon extension, growth, and even cell attach-
ment to substrate in vitro. Although there is evidence
that MSCs promote cell growth and repair in the brain,
it has not yet been definitively confirmed that MSCs
can become mature nerve cells with the ability to sig-
nal, or communicate with, other nerve cells [94–96].
Mesenchymal stem cells in vivo and the host immune system
Many experiments have been carried out in which MSCs
are transplanted into other organisms of the same or of
different species. These cells are not rejected because
MSCs have very low levels of MHC class II proteins and
lack MHC class I proteins and cannot, therefore, present
exogenous antigens to the recipient (host) organism
[97–100]. As a result, they are perceived as endogenous.
MSCs also interact with the host immune and inflamma-
tory systems in other ways, as discussed below.
When human MSCs are labeled in order to track their
migration and then injected into mice that have some type
of tissue damage, they migrate evenly throughout the
damaged tissues. These cells may or may not be present in
the tissue for a substantial period of time, which depends
on many factors, such as cell type, animal model, time of
cell transplantation, and so on. The continued presence of
MSCs is important, but not essential, in therapeutic treat-
ments because it demonstrates the potential for positive
long-term effects of transplantation. It is important to
realize that the temporary presence of MSCs is not a re-
sult of the host immune response, since experiments in
injured mice with and without functional immune sys-
tems yield the same results. Further investigations show
that MSCs suppress the immune system and reduce in-
flammation [101]. In brain injury models, MSC treat-
ment reduces the presence of microglia in the damaged
brain and decreases the number of peripheral infiltrat-
ing leukocytes at the injured site by increasing anti-
inflammatory cytokines [102]. In other words, MSCs
can be transferred between organisms without eliciting
immune rejection by the host, which renders them very
good candidates for transplantation, immunosuppres-
sion and immunomodulation [100, 103–107].
Routes of mesenchymal stem cell transplantation and
penetration through the blood–brain barrier
A crucial issue in cellular therapies for HD is the route
of MSC delivery into the brain, which has been
approached in a number of different ways. Several ad-
ministration routes have been proposed to deliver
MSCs into the CNS, such as intracerebral (hemisphere
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plus IV into the space surrounding the spinal cord, and
even intranasal [108, 109].
The blood–brain barrier (BBB) is formed in early em-
bryological development through complex multicellular
interactions between immature endothelial cells and
neural progenitors, neurons, radial glia, and finally peri-
cytes, which share similar features with MSCs. It select-
ively controls molecular and cellular trafficking between
the bloodstream and brain interstitial space, which is a
concern when considering routes of drug and cell deliv-
ery to treat brain malignancies and neurodegenerative
disorders. Systemically infused MSCs may be able to
treat acute injuries, inflammatory diseases, CNS stroke
and even brain tumors because of their regenerative cap-
acity and ability to secrete trophic, immunomodulatory,
growth or other engineered therapeutic factors. How-
ever, whether MSCs possess the ability to migrate across
the BBB in vivo under both normal and pathological
conditions remains poorly resolved [110]. Systemic infu-
sion (that is, IV) of in vitro expanded MSCs is a minim-
ally invasive and convenient procedure that is used in a
large number of ongoing clinical trials: acute graft-
versus-host disease [111], acute myocardial function
[112, 113], liver disease [114] and multiple sclerosis
[115]. Therefore, it is essential to verify whether trans-
planted MSCs can home to and engraft at ischemic and
injured sites in the brain in order to exert their thera-
peutic effects. During brain inflammation and injury, the
BBB becomes compromised, allowing cellular trafficking
through the BBB, including leukocyte trafficking to sites
of CNS inflammation, as has been well studied and ex-
tensively reviewed [116, 117]. Several recent studies sug-
gest that adipose tissue- and bone marrow-derived
MSCs may possess leukocyte-like activities that enable
them to interact with and migrate across the BBB after
injury or inflammation [110, 118–120]. It is suggested
that MSCs can transmigrate across the brain vascular
endothelial monolayer through transiently formed inter-
endothelial gaps [121]. Given that MSCs have this ability
to transmigrate across the BBB, they can be adminis-
tered IV, which is not as invasive as the intrathecal or in-
tracerebral (for example, in striatum) routes [65].Mesenchymal stem cells in Huntington’s disease animal
models
The ‘simplicity’ with which MSCs can be obtained and
cultured, as well as their unique trophic activities and
the possibility of their transfer into the host without im-
mune rejection, are the reasons why we are hopeful that
MSCs may offer a promising way to develop treatments
for neurodegeneration. Table 2 summarizes published
data on MSC transplantation into HD animal models.Note that none of the published HD animal studies used
systemic (IV) MSC transplantation. Table 2 also shows the
types of cells used as origin and pre-treatment. Allogeneic
and xenogeneic, primary cultures and immortalized cell
lines from bone marrow, adipose tissue and umbilical cord
blood, grown under normal levels of oxygen (normoxia)
and under low levels of oxygen (hypoxia), have been used
[61, 96, 122–125].
The majority of cells used in vivo in HD models are
referred to as MSCs, multipotent stromal cells or adi-
pose tissue-derived stem cells. However, most published
articles do not demonstrate that the cells used present
the typical MSC immunophenotype in accordance with
the minimal criteria for defining multipotent mesenchy-
mal stromal cells, as established by The International So-
ciety for Cellular Therapy [95]. Snyder and co-workers
[96] are the only ones who show that, among other cell
markers, the cells used in their study also express CD90
and CD105, which are considered markers of MSCs.
While only one study reported that mouse umbilical cord
blood (mUCB)-derived MSCs do not express MHC class
II cell surface molecules [122], other authors did not pro-
vide such information. A few publications report that the
cells used express neurotrophic factor genes, but they do
not clarify whether the products of these genes are trans-
lated into protein [61, 122, 126] (Table 2).
All studies used cells at passages no higher than 10,
excluding one study, which used mUCB-derived MSCs
at passages 40 and 50 [122]. Interestingly, these authors
observed that the expression of pluripotent stem cell
markers, such as SSEA4 (stage-specific embryonic antigen
4), increases with the passages, as well as that transplant-
ation of high-passage mUCB-derived MSCs confers sig-
nificant motor benefits compared with that of low-passage
mUCB-derived MSCs. However, the use of MSCs from
later passages is not usual in animal and clinical studies
due to chromosomal instability.
Cell doses per transplantation and cell tracer use vary
between studies. Each has their advantages and disadvan-
tages, as discussed in the ‘Neural stem cells/progenitor
cells’ section of this review; taken together, however, they
confirm that MSCs reach and engraft into the damaged
areas of brain in HD animal models. These methods also
show that the cell graft is mainly restricted to the stria-
tum—the cells are found near the transplantation site,
forming a lump, and show no or very limited migration.
In one study, the authors observed that the cells are
mainly localized near blood vessels and lateral ventricles
in both hemispheres [125]. The low migration capacity
of MSCs can be partly explained by application of the
cells directly to the injured site [127], which does not
provide stimulus for their migration due to the inflam-
mation process that ensues, which is very chemoattrac-
tive for MSCs. This, for example, has been shown in
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retriever model, whereby, after intramuscular transplant-
ation, MSCs do not migrate from the region of local
muscle application [87].
Different chemical (QA and 3-NP) and genetic
models (R6/2-J2, N171-82Q, R6/2) of HD have been
used in MSC transplantation studies (Table 2). There is
no standardization with respect to time interval be-
tween MSC transplantation and analysis of results
(Table 2). The studies which analyze survival of MSC
post-transplantation note short-term survival of trans-
planted cells and reduction of apoptosis of intrinsic cells
[61, 96, 124]. Most authors report that transplanted cells
remain undifferentiated post-graft [61, 96, 122, 126],
which supports the statement that MSC activity is similar
to that of CNS microvascular pericytes [128]. These latter
cells have critical and complex inductive, structural, and
regulatory roles, interacting with other cell types of the
neurovascular unit, especially endothelial cells and astro-
cytes [110]. On the other hand, several studies demon-
strate expression of neuronal markers in transplanted
cells, such as Rbfox3 (RNA binding protein, fox-1 homo-
log 3, also known as NeuN), which is a neuron-specific
nuclear protein; however, NeuN appears to be devoid of
immunoreactivity towards cerebellar Purkinje cells [129].
In general, all studies carried out in HD animal
models using MSC transplantation observed behavioral
and memory improvements, reduced brain damage and
amelioration of striatal degeneration, and enhanced ex-
pression of several striatal growth factors. Most authors
attribute these results to the neuroprotective effect of
MSCs (Table 2).
Stem cells in Huntington’s disease clinical investigations
The prospect of using stem cells to intervene in neuro-
degenerative disease is promising. To date, however, only
a small number of clinical trials has been undertaken,
whereby fetal donor tissues have been transplanted into
the striatum [130]. Cell therapies in HD are intended to
protect neuronal populations that are susceptible to the
disease and/or replace dysfunctional or dying neurons.
Clinical progress in HD cell therapy has centered on es-
tablishing protocols for transplanting fetal-derived cells
into the diseased striatum. This strategy is stimulating
the development of stem cell therapy in the clinic and
has been shown to provide patients with a period of
several years of improvement and stability, but not with
a permanent cure for the disease [131]. A long-term
follow-up of patients over a 3- to 10-year postoperative
period shows that fetal striatal allograft in HD is safe,
although this study showed no sustained functional
benefit [1]. The authors suggest that such a result is
due to the small amount of cells that were grafted in
this safety study compared with other reports of moresuccessful transplants in patients with HD [1]. This obs-
tacle can be overcome with new cell technologies, which
allow stem cell in vitro expansion, while preserving their
natural capacity for self-renewal and differentiation.
Conclusion
The animal studies discussed in this review agree that
NSC/progenitor cell and MSC transplantation can be
beneficial, with partial functional and anatomical recov-
ery, reduced cell death, reduced brain damage, increased
endogenous cell proliferation and even partial differenti-
ation of transplanted cells towards neurons (summarized
in Fig. 1). More importantly, studies have even demon-
strated reduced formation of ubiquitin aggregates upon
adipose cell-derived MSC transplantation into HD mice
[123] or when NSC therapy is associated with trehalose
administration [132]. However, several points still need
to be considered and answered using animal models.
It is worth mentioning that both the design of animal
studies and the characterization of transplanted cells are
poorly standardized and that this greatly complicates com-
parative analysis. In the future, an agreement between re-
searchers must be reached in order to standardize marker
use to enable study comparison and reproducibility.
It seems that NSCs/progenitor cells and MSCs can be
used interchangeably. However, MSCs have an advantage
over NSCs/progenitor cells in that there are fewer ethical
considerations regarding their extraction and because they
are easy to isolate and expand in vitro. Primary cultures of
NSCs/progenitor cells are usually heterogeneous, contain-
ing many cell types, which makes characterization harder
and experiments less reproducible. Moreover, MSCs are
non-immunogenic, while neural stem/progenitor cells
may require a co-application of an immunosuppression
protocol (Fig. 1).
As to cell numbers (best dose) at transplantation, there
does not seem to be any consensus. Fewer cells are
probably best to avoid tissue damage upon transplant-
ation. On the other hand, the population must be large
enough to guarantee that sufficient cells can reach the
area of tissue damage and promote recovery. Trans-
planted cells should be able to reproduce in the recipient
organism while still undifferentiated, but their number
should not be increased drastically in order to avoid
carcinogenesis.
The administration route of stem cell transplantation
should be revised, considering that local injections are
extremely invasive and that NSCs/progenitor cells and
MSCs do not show efficient migratory capacity, as ex-
tensively reviewed by Reyes and colleagues [133], among
others [61, 87, 123, 126, 127, 133].
In chemical models, the cells are usually administered
after HD induction with the drug, while, in transgenic
animals, cell administration time depends on disease
Fig. 1 Effect of neural stem cells/progenitor cells and mesenchymal stem cell transplantation on Huntington’s disease etiology and progression.
Huntington’s disease (HD) is caused by an expansion of (polyQ) repeats within the amino terminus of the huntingtin (HTT) protein, which promotes
HTT aggregation and formation of intracellular inclusion bodies. These events lead to microglial activation, which correlates with striatal neuronal
dysfunction and neuronal death as well as with reduced expression of striatal D1 and D2 receptors and of neurotrophic factors [136, 137]. In turn,
striatal neuronal dysfunction correlates with cortex atrophy, motor deficits and cognitive deficits in HD patients. According to the most updated
literature on HD, both neural stem cells (NSCs)/progenitor cells and mesenchymal stem cells (MSCs) improve motor coordination, behavior and
memory. NSCs/progenitor cells and MSCs also seem to be able to reduce formation of HTT-ubiquitin aggregates. HD improvements occur as a result
of NSC/progenitor cell and MSC transplantation through very similar mechanisms, such as immunomodulation, trophic properties, neurotrophic
support and neuronal protection. These mechanisms are well known for MSCs and only marginally recognized for NSCs/progenitor cells [79, 94]. Until
now, the great advantage of MSCs, in comparison with NSCs/progenitor cells, are their immunoprivileged properties, few or lack of ethical concerns
regarding their origin, significant therapeutic quantities, non-teratogenicity (safety), as well as immunomodulation. Although in vivo differentiation of
both cell types has been demonstrated, it is not clear if the number of differentiated cells is sufficient to justify all brain improvements found upon
transplantation or whether changes are due to intrinsic cell regeneration. mHTT mutant huntingtin
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considered in order to derive the most benefit from the
stem cell-based therapy.
So far, all animal and clinical study protocols for HD
used only one course of cell transplantation. This is not
compatible with the neurodegenerative character of the
disease. In HD patients, the degenerative process is pro-
gressive and stem cell-based therapies should, therefore,
be applied regularly. The point at which the therapy
should begin and the time intervals between cell trans-
plantations can vary significantly and are questions to be
answered in future studies.
It is still unclear from animal studies how transplanted
cells regulate the expression pattern of inflammatory cyto-
kines and chemokines, as well as that of neurotrophic fac-
tors, which are also concerns that should be addressed
before clinical trials.Finally, HD therapy protocols using stem cells should be
developed not only for treating the clinical onset of HD
but also to prevent HD development [134]. The establish-
ment of new methods to quantify mHTT in cerebrospinal
fluid may facilitate the study of HD, since mHTT could
potentially serve as a biomarker for the development and
testing of experimental mHTT-lowering cell therapies for
HD [135].Abbreviations
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